Global Endophthalmitis Treatment Market

Endophthalmitis Treatment Comprehensive Study by Type (Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}, Endogenous), Meditation (Antibiotics, Corticosteroid), End user (Hospitals pharmacies, Ophthalmology Clinics, Others) Players and Region - Global Market Outlook to 2030

Endophthalmitis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Endophthalmitis Treatment
Endophthalmitis is a disease of eye, it causes inflammation of the interior cavity of the eye, usually caused by infection. Infection can be caused by fungi, Viruses, bacteria by direct inoculation as in surgery or penetrating trauma or by blood vessels to the eye from another site of infection. In Endophthalmitis treatment antibiotics are placed into the eye with a tiny needle and some cases corticosteroid may be added to reduce swelling.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Endophthalmitis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Celerity Pharmaceuticals (United States), F. Hoffmann-La Roche Ltd (Switzerland), Allergan (United States), GlaxoSmithKline plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan), Jina Pharma (United States), Bayer AG (Germany), Merck Sharp & Dohme Corp (United States) and Eye Health America (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sanofi (France), Novartis (Switzerland) and Merck Sharp & Dohme Corp. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Endophthalmitis Treatment market by and Region.



On the basis of geography, the market of Endophthalmitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Type, the sub-segment i.e. Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer} will boost the Endophthalmitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Meditation, the sub-segment i.e. Antibiotics will boost the Endophthalmitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End user, the sub-segment i.e. Hospitals pharmacies will boost the Endophthalmitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Increasing Infectious conjunctivitis due to use of chlorine in swimming pool., Rising neovascular age-related macular degeneration disease. and Increasing trend of eye tattoo and related infections

Challenges:
High cost of treatment.

Restraints:
In treatment lens capsule rupture.

Opportunities:
Rising Healthcare Expenditure.

Market Leaders and their expansionary development strategies
In July 2023, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first and only FDA approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
In October 2021- Food and Drug Administration (FDA) has approved ranibizumab injection for intravitreal use via ocular implant for the treatment of people with neovascular age-related macular degeneration (nAMD).
IDSA guidelines for the treatment of Aspergillus Endophthalmitis treatment recommend the use of IV amphotericin B with addition of intravitreal amphotericin B and pars plana vitrectomy for sight-threatening cases.

Key Target Audience
Government Regulatory and Research Organizations, Pharmaceutical industries and Hospitals

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}
  • Endogenous

By Meditation
  • Antibiotics
  • Corticosteroid

By End user
  • Hospitals pharmacies
  • Ophthalmology Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Infectious conjunctivitis due to use of chlorine in swimming pool.
      • 3.2.2. Rising neovascular age-related macular degeneration disease.
      • 3.2.3. Increasing trend of eye tattoo and related infections
    • 3.3. Market Challenges
      • 3.3.1. High cost of treatment.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Endophthalmitis Treatment, by Type, Meditation, End user and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Endophthalmitis Treatment (Value)
      • 5.2.1. Global Endophthalmitis Treatment by: Type (Value)
        • 5.2.1.1. Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}
        • 5.2.1.2. Endogenous
      • 5.2.2. Global Endophthalmitis Treatment by: Type (Value)
        • 5.2.2.1. Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}
        • 5.2.2.2. Endogenous
      • 5.2.3. Global Endophthalmitis Treatment by: Meditation (Value)
        • 5.2.3.1. Antibiotics
        • 5.2.3.2. Corticosteroid
      • 5.2.4. Global Endophthalmitis Treatment by: End user (Value)
        • 5.2.4.1. Hospitals pharmacies
        • 5.2.4.2. Ophthalmology Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Endophthalmitis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Endophthalmitis Treatment (Price)
  • 6. Endophthalmitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celerity Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Santen Pharmaceutical Co. Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Jina Pharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck Sharp & Dohme Corp (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eye Health America (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Endophthalmitis Treatment Sale, by Type, Meditation, End user and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Endophthalmitis Treatment (Value)
      • 7.2.1. Global Endophthalmitis Treatment by: Type (Value)
        • 7.2.1.1. Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}
        • 7.2.1.2. Endogenous
      • 7.2.2. Global Endophthalmitis Treatment by: Type (Value)
        • 7.2.2.1. Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}
        • 7.2.2.2. Endogenous
      • 7.2.3. Global Endophthalmitis Treatment by: Meditation (Value)
        • 7.2.3.1. Antibiotics
        • 7.2.3.2. Corticosteroid
      • 7.2.4. Global Endophthalmitis Treatment by: End user (Value)
        • 7.2.4.1. Hospitals pharmacies
        • 7.2.4.2. Ophthalmology Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Endophthalmitis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Endophthalmitis Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Endophthalmitis Treatment: by Type(USD Million)
  • Table 2. Endophthalmitis Treatment Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer} , by Region USD Million (2018-2023)
  • Table 3. Endophthalmitis Treatment Endogenous , by Region USD Million (2018-2023)
  • Table 4. Endophthalmitis Treatment: by Type(USD Million)
  • Table 5. Endophthalmitis Treatment Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer} , by Region USD Million (2018-2023)
  • Table 6. Endophthalmitis Treatment Endogenous , by Region USD Million (2018-2023)
  • Table 7. Endophthalmitis Treatment: by Meditation(USD Million)
  • Table 8. Endophthalmitis Treatment Antibiotics , by Region USD Million (2018-2023)
  • Table 9. Endophthalmitis Treatment Corticosteroid , by Region USD Million (2018-2023)
  • Table 10. Endophthalmitis Treatment: by End user(USD Million)
  • Table 11. Endophthalmitis Treatment Hospitals pharmacies , by Region USD Million (2018-2023)
  • Table 12. Endophthalmitis Treatment Ophthalmology Clinics , by Region USD Million (2018-2023)
  • Table 13. Endophthalmitis Treatment Others , by Region USD Million (2018-2023)
  • Table 14. South America Endophthalmitis Treatment, by Country USD Million (2018-2023)
  • Table 15. South America Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 16. South America Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 17. South America Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 18. Brazil Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 19. Brazil Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 20. Brazil Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 21. Argentina Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 22. Argentina Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 23. Argentina Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 24. Rest of South America Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 26. Rest of South America Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 27. Asia Pacific Endophthalmitis Treatment, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 30. Asia Pacific Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 31. China Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 32. China Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 33. China Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 34. Japan Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 35. Japan Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 36. Japan Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 37. India Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 38. India Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 39. India Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 40. South Korea Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 41. South Korea Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 42. South Korea Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 43. Australia Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 44. Australia Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 45. Australia Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 49. Europe Endophthalmitis Treatment, by Country USD Million (2018-2023)
  • Table 50. Europe Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 51. Europe Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 52. Europe Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 53. Germany Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 54. Germany Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 55. Germany Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 56. France Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 57. France Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 58. France Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 59. Italy Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 60. Italy Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 61. Italy Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 62. United Kingdom Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 64. United Kingdom Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 65. Netherlands Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 66. Netherlands Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 67. Netherlands Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 68. Rest of Europe Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 70. Rest of Europe Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 71. MEA Endophthalmitis Treatment, by Country USD Million (2018-2023)
  • Table 72. MEA Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 73. MEA Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 74. MEA Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 75. Middle East Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 76. Middle East Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 77. Middle East Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 78. Africa Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 79. Africa Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 80. Africa Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 81. North America Endophthalmitis Treatment, by Country USD Million (2018-2023)
  • Table 82. North America Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 83. North America Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 84. North America Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 85. United States Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 86. United States Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 87. United States Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 88. Canada Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 89. Canada Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 90. Canada Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 91. Mexico Endophthalmitis Treatment, by Type USD Million (2018-2023)
  • Table 92. Mexico Endophthalmitis Treatment, by Meditation USD Million (2018-2023)
  • Table 93. Mexico Endophthalmitis Treatment, by End user USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Endophthalmitis Treatment: by Type(USD Million)
  • Table 105. Endophthalmitis Treatment Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer} , by Region USD Million (2025-2030)
  • Table 106. Endophthalmitis Treatment Endogenous , by Region USD Million (2025-2030)
  • Table 107. Endophthalmitis Treatment: by Type(USD Million)
  • Table 108. Endophthalmitis Treatment Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer} , by Region USD Million (2025-2030)
  • Table 109. Endophthalmitis Treatment Endogenous , by Region USD Million (2025-2030)
  • Table 110. Endophthalmitis Treatment: by Meditation(USD Million)
  • Table 111. Endophthalmitis Treatment Antibiotics , by Region USD Million (2025-2030)
  • Table 112. Endophthalmitis Treatment Corticosteroid , by Region USD Million (2025-2030)
  • Table 113. Endophthalmitis Treatment: by End user(USD Million)
  • Table 114. Endophthalmitis Treatment Hospitals pharmacies , by Region USD Million (2025-2030)
  • Table 115. Endophthalmitis Treatment Ophthalmology Clinics , by Region USD Million (2025-2030)
  • Table 116. Endophthalmitis Treatment Others , by Region USD Million (2025-2030)
  • Table 117. South America Endophthalmitis Treatment, by Country USD Million (2025-2030)
  • Table 118. South America Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 119. South America Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 120. South America Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 121. Brazil Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 122. Brazil Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 123. Brazil Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 124. Argentina Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 125. Argentina Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 126. Argentina Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 127. Rest of South America Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 128. Rest of South America Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 129. Rest of South America Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 130. Asia Pacific Endophthalmitis Treatment, by Country USD Million (2025-2030)
  • Table 131. Asia Pacific Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 132. Asia Pacific Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 133. Asia Pacific Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 134. China Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 135. China Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 136. China Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 137. Japan Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 138. Japan Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 139. Japan Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 140. India Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 141. India Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 142. India Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 143. South Korea Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 144. South Korea Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 145. South Korea Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 146. Australia Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 147. Australia Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 148. Australia Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 152. Europe Endophthalmitis Treatment, by Country USD Million (2025-2030)
  • Table 153. Europe Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 154. Europe Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 155. Europe Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 156. Germany Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 157. Germany Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 158. Germany Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 159. France Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 160. France Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 161. France Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 162. Italy Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 163. Italy Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 164. Italy Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 165. United Kingdom Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 166. United Kingdom Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 167. United Kingdom Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 168. Netherlands Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 169. Netherlands Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 170. Netherlands Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 171. Rest of Europe Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 172. Rest of Europe Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 173. Rest of Europe Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 174. MEA Endophthalmitis Treatment, by Country USD Million (2025-2030)
  • Table 175. MEA Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 176. MEA Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 177. MEA Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 178. Middle East Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 179. Middle East Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 180. Middle East Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 181. Africa Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 182. Africa Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 183. Africa Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 184. North America Endophthalmitis Treatment, by Country USD Million (2025-2030)
  • Table 185. North America Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 186. North America Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 187. North America Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 188. United States Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 189. United States Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 190. United States Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 191. Canada Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 192. Canada Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 193. Canada Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 194. Mexico Endophthalmitis Treatment, by Type USD Million (2025-2030)
  • Table 195. Mexico Endophthalmitis Treatment, by Meditation USD Million (2025-2030)
  • Table 196. Mexico Endophthalmitis Treatment, by End user USD Million (2025-2030)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Endophthalmitis Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Endophthalmitis Treatment: by Type USD Million (2018-2023)
  • Figure 6. Global Endophthalmitis Treatment: by Meditation USD Million (2018-2023)
  • Figure 7. Global Endophthalmitis Treatment: by End user USD Million (2018-2023)
  • Figure 8. South America Endophthalmitis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Endophthalmitis Treatment Share (%), by Country
  • Figure 10. Europe Endophthalmitis Treatment Share (%), by Country
  • Figure 11. MEA Endophthalmitis Treatment Share (%), by Country
  • Figure 12. North America Endophthalmitis Treatment Share (%), by Country
  • Figure 13. Global Endophthalmitis Treatment share by Players 2023 (%)
  • Figure 14. Global Endophthalmitis Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Endophthalmitis Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2023
  • Figure 19. Celerity Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 20. Celerity Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 23. Allergan (United States) Revenue, Net Income and Gross profit
  • Figure 24. Allergan (United States) Revenue: by Geography 2023
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Santen Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Santen Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2023
  • Figure 29. Jina Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 30. Jina Pharma (United States) Revenue: by Geography 2023
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 33. Merck Sharp & Dohme Corp (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck Sharp & Dohme Corp (United States) Revenue: by Geography 2023
  • Figure 35. Eye Health America (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eye Health America (United States) Revenue: by Geography 2023
  • Figure 37. Global Endophthalmitis Treatment: by Type USD Million (2025-2030)
  • Figure 38. Global Endophthalmitis Treatment: by Type USD Million (2025-2030)
  • Figure 39. Global Endophthalmitis Treatment: by Meditation USD Million (2025-2030)
  • Figure 40. Global Endophthalmitis Treatment: by End user USD Million (2025-2030)
  • Figure 41. South America Endophthalmitis Treatment Share (%), by Country
  • Figure 42. Asia Pacific Endophthalmitis Treatment Share (%), by Country
  • Figure 43. Europe Endophthalmitis Treatment Share (%), by Country
  • Figure 44. MEA Endophthalmitis Treatment Share (%), by Country
  • Figure 45. North America Endophthalmitis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Celerity Pharmaceuticals (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Allergan (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Santen Pharmaceutical Co. Ltd. (Japan)
  • Jina Pharma (United States)
  • Bayer AG (Germany)
  • Merck Sharp & Dohme Corp (United States)
  • Eye Health America (United States)
Additional players considered in the study are as follows:
Sanofi (France) , Novartis (Switzerland) , Merck Sharp & Dohme Corp. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 167 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Endophthalmitis Treatment Market Quantitative research analysis
Global Endophthalmitis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Celerity Pharmaceuticals (United States), F. Hoffmann-La Roche Ltd (Switzerland), Allergan (United States), GlaxoSmithKline plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan), Jina Pharma (United States), Bayer AG (Germany), Merck Sharp & Dohme Corp (United States) and Eye Health America (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Endophthalmitis Treatment Market during projected period 2023-2030.
The Endophthalmitis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Endophthalmitis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Medical Second Opinion Services- Comprehensive Study by Application (Patients, Families), Service providers (Hospitals, Medical second opinion providing companies, Health insurance companies), Diseas...
$ 3650
Surgery Management Solutions Comprehensive Study by Type (Services, Software), Application (Anesthesia Information Management Systems, Data Management and Communication Solutions, Operating Room Supp...
$ 3800
Mitral Regurgitation Comprehensive Study by Type (Chronic, Acute), Treatment (Mitral Valve Repair, Medical Therapy, Mitral Valve Replacement, Anticoagulants, Angiotensin-Converting Enzyme (ACE) Inhib...
$ 3800
Dental Care Services Comprehensive Study by Type (Endodontic, Prosthodontics, Implantology, Orthodontics, Cosmetic Dentistry, Periodontics), Income Group (Higher Class, Upper-Middle Class, Lower-Midd...
$ 3800
Virtual Companion Care Comprehensive Study by Type (Medication Management Service, Personal Safety Monitoring Service), Application (Rehabilitation Centers, Long-term Care Centers, Home Care Settings...
$ 3800
Doctor House Calls- Comprehensive Study by Type (Primary Care, Mobile Clinical Testing, Chronic Care Management, Urgent Care, Preventive Care, Others), Application (Below 55 years, Above 55 years), P...
$ 3800